[{"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q1_USD":66604.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1_Q1_USD":-143607.0,"IncreaseDecreaseInPrepaidExpense_1_Q1_USD":26831.0,"PrepaidExpenseCurrent_0_Q1_USD":118981.0,"BusinessAcquisitionPercentageOfVotingInterestsAcquired_0_Q1_pure":0.5,"DeferredTaxLiabilities_0_Q1_USD":90277.0,"NonoperatingIncomeExpense_1_Q1_USD":1538965.0,"StockRepurchasedAndRetiredDuringPeriodShares_1_Q1_shares":null,"TaxesPayableCurrent_0_Q1_USD":62092.0,"CashFDICInsuredAmount_0_Q1_USD":250000.0,"DeferredIncomeTaxExpenseBenefit_1_Q1_USD":91930.0,"IncomeTaxesPaid_1_Q1_USD":137500.0,"InvestmentIncomeInterest_1_Q1_USD":1109075.0,"OperatingCostsAndExpenses_1_Q1_USD":241639.0,"UnrealizedGainLossOnSecurities_1_Q1_USD":429890.0,"AssetsHeldInTrustNoncurrent_0_Q1_USD":291996005.0,"DeferredOfferingCosts_0_Q1_USD":16473117.0,"ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_1_Q1_USD":5000000.0,"IncreaseDecreaseInAccruedIncomeTaxesPayable_1_Q1_USD":43209.0,"InterestExpenseTrustPreferredSecurities_1_Q1_USD":788500.0,"PaymentsOfStockIssuanceCosts_1_Q1_USD":null,"ProceedsFromSaleOfTrustAssetsToPayExpenses_1_Q1_USD":137500.0,"RedeemableNoncontrollingInterestEquityCarryingAmount_0_Q1_USD":276588435.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q1_USD":-127904.0,"PreferredStockValue_0_Q1_USD":null,"PreferredStockSharesOutstanding_0_Q1_shares":null,"PreferredStockSharesIssued_0_Q1_shares":null,"AdditionalPaidInCapital_0_Q1_USD":1462578.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":21375000.0,"Assets_0_Q1_USD":292619916.0,"AssetsCurrent_0_Q1_USD":623911.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":504930.0,"CashAndCashEquivalentsPeriodIncreaseDecrease_1_Q1_USD":-412077.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.01,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":1297326.0,"IncomeTaxExpenseBenefit_1_Q1_USD":272639.0,"Liabilities_0_Q1_USD":11031473.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":292619916.0,"LiabilitiesCurrent_0_Q1_USD":128696.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":null,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":137500.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-549577.0,"NetIncomeLoss_1_Q1_USD":1024687.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":3536560.0,"StockholdersEquity_0_Q1_USD":5000008.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":8654017.0,"CommitmentsAndContingencies_0_Q1_USD":null,"OperatingIncomeLoss_1_Q1_USD":-241639.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"PreferredStockSharesAuthorized_0_Q1_shares":1000000.0,"StockRedeemedOrCalledDuringPeriodValue_1_Q1_USD":-1024684.0,"TemporaryEquityAccretionToRedemptionValueAdjustment_1_Q1_USD":1152591.0,"Ticker":"CELU","CIK":"1752828","name":"GX ACQUISITION CORP.","OfficialName":"Celularity Inc. Class A Common Stock","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1622347796.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200515"}]